![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Nonprofit Puts Pressure on NIH for March-in Rights
Nonprofit Puts Pressure on NIH for March-in Rights
April 5, 2016
A nonprofit group is pressing NIH to bypass the patent rights of a company in a bid to lower the drug’s price, marking at least the third time the group has attempted this.
A petition sent to NIH in January by Knowledge Ecology International asked it to exercise march-in rights — a regulatory mechanism for bypassing exclusivity rights to a patent if it was developed with public funding — over the price of Astellas Pharmaceuticals’ cancer drug Xtandi. Joining the group in this effort is the Union for Affordable Cancer Treatment.
The pair proposed the use of this little-known provision — which NIH has never exercised — of the 1980 Bayh-Dole Act to force Astellas to drop the price of the drug, which costs $88 per pill, or $129,000 per year.
Upcoming Events
-
21Oct